Trials / Completed
CompletedNCT02733445
Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,650 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine how often and how likely patients are to develop Type 2 Diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy for Chronic Myelogenous Leukemia (CML).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dasatinib | |
| DRUG | nilotinib |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2015-12-01
- Completion
- 2016-03-01
- First posted
- 2016-04-11
- Last updated
- 2016-04-11
Source: ClinicalTrials.gov record NCT02733445. Inclusion in this directory is not an endorsement.